Bavarian Nordic A/S has agreed to sell a priority review voucher that was obtained through the development of a smallpox and monkeypox vaccine for $95 million in cash.
The Danish biotechnology company did not disclose the buyer. The transaction is subject to customary closing conditions including antitrust review, which is expected to occur in early 2020.
The U.S. Food and Drug Administration granted Bavarian Nordic the priority review voucher in September upon the approval of the smallpox and monkeypox vaccine Jynneos.
Holders of priority review vouchers are granted accelerated review from the FDA for future human drug applications.
Jefferies International Ltd. served as the exclusive financial adviser to Bavarian Nordic for the sale.